BACKGROUND: High fasting insulin levels have been reported to predict development of observed apneas, suggesting that insulin resistance may contribute to the pathogenesis of obstructive sleep apnea (OSA). The aim of this study was to determine whether enhancing insulin sensitivity in individuals with OSA would improve sleep measures. PATIENTS/ METHODS: Insulin-resistant, nondiabetic individuals with untreated OSA were randomized (2:1) to pioglitazone (45 mg/day) or placebo for eight weeks in this single-blind study. All individuals had repeat measurements pertaining to sleep (overnight polysomnography and functional outcomes of sleep questionnaire) and insulin action (insulin suppression test). RESULTS: A total of 45 overweight/obese men and women with moderate/severe OSA were randomized to pioglitazone (n = 30) or placebo (n = 15). Although insulin sensitivity increased 31% among pioglitazone-treated compared with no change among individuals receiving placebo (p <0.001 for between-group difference), no improvement in quantitative or qualitative sleep measurements was observed. CONCLUSIONS: Pioglitazone administration increased insulin sensitivity in otherwise untreated individuals with OSA, without any change in polysomnographic sleep measures over an eight-week period. These findings do not support a causal role for insulin resistance in the pathogenesis of OSA.
RCT Entities:
BACKGROUND: High fasting insulin levels have been reported to predict development of observed apneas, suggesting that insulin resistance may contribute to the pathogenesis of obstructive sleep apnea (OSA). The aim of this study was to determine whether enhancing insulin sensitivity in individuals with OSA would improve sleep measures. PATIENTS/ METHODS:Insulin-resistant, nondiabetic individuals with untreated OSA were randomized (2:1) to pioglitazone (45 mg/day) or placebo for eight weeks in this single-blind study. All individuals had repeat measurements pertaining to sleep (overnight polysomnography and functional outcomes of sleep questionnaire) and insulin action (insulin suppression test). RESULTS: A total of 45 overweight/obesemen and women with moderate/severe OSA were randomized to pioglitazone (n = 30) or placebo (n = 15). Although insulin sensitivity increased 31% among pioglitazone-treated compared with no change among individuals receiving placebo (p <0.001 for between-group difference), no improvement in quantitative or qualitative sleep measurements was observed. CONCLUSIONS:Pioglitazone administration increased insulin sensitivity in otherwise untreated individuals with OSA, without any change in polysomnographic sleep measures over an eight-week period. These findings do not support a causal role for insulin resistance in the pathogenesis of OSA.
Authors: Joshua W Knowles; Themistocles L Assimes; Philip S Tsao; Andrea Natali; Andrea Mari; Thomas Quertermous; Gerald M Reaven; Fahim Abbasi Journal: Metabolism Date: 2012-11-12 Impact factor: 8.694
Authors: Clete A Kushida; Alejandro Chediak; Richard B Berry; Lee K Brown; David Gozal; Conrad Iber; Sairam Parthasarathy; Stuart F Quan; James A Rowley Journal: J Clin Sleep Med Date: 2008-04-15 Impact factor: 4.062
Authors: Lana J Mitchell; Zoe E Davidson; Maxine Bonham; Denise M O'Driscoll; Garun S Hamilton; Helen Truby Journal: Sleep Med Date: 2014-06-25 Impact factor: 3.492
Authors: Alice Liu; Fahim Abbasi; Sun H Kim; Danit Ariel; Cindy Lamendola; James Cardell; Shiming Xu; Shailja Patel; Vanessa Tomasso; Hafasa Mojaddidi; Kaylene Grove; Philip S Tsao; Clete A Kushida; Gerald M Reaven Journal: Am J Cardiol Date: 2017-01-25 Impact factor: 2.778
Authors: Renae C Fernandez; Vivienne M Moore; Emer M Van Ryswyk; Tamara J Varcoe; Raymond J Rodgers; Wendy A March; Lisa J Moran; Jodie C Avery; R Doug McEvoy; Michael J Davies Journal: Nat Sci Sleep Date: 2018-02-01
Authors: Charlotte E Edling; Ibrahim T Fazmin; Karan R Chadda; Shiraz Ahmad; Haseeb Valli; Christopher L-H Huang; Kamalan Jeevaratnam Journal: Front Physiol Date: 2019-04-24 Impact factor: 4.566